Arcus Biosciences RCUS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $236M+67.4% | $247M-4.3% | $240M-8.7% | $262M+6.1% | $141M-40.5% | ||
| $523M+13.4% | $523M+16.7% | $503M+14.3% | $485M+21.6% | $461M+25.3% | ||
| $111M-4.3% | $110M-8.3% | $112M-7.4% | $115M-5.0% | $116M-2.5% | ||
| $634M+9.9% | $633M+7.7% | $615M+5.9% | $600M+11.1% | $577M+13.8% | ||
| $634M+9.9% | $633M+7.7% | $615M+5.9% | $600M+11.1% | $577M+13.8% | ||
| -$398M+8.7% | -$386M-17.0% | -$375M-17.9% | -$338M-15.4% | -$436M-61.5% | ||
| -168.6%+141pp | -156.3%-28.4pp | -156.3%-35.3pp | -129%-10.4pp | -309.2%-195pp | ||
| $10M+150% | $8M+100% | $8M— | $6M— | $4M— | ||
| $29M-37.0% | $33M-31.3% | $35M-28.6% | $41M-12.8% | $46M+7.0% | ||
| -$369M+5.4% | -$353M-25.2% | -$340M-26.4% | -$297M-20.7% | -$390M-71.8% | ||
| $0-100% | $0-100% | $1M0.0% | $1M-66.7% | $1M-75.0% | ||
| -$369M+5.6% | -$353M-24.7% | -$341M-26.3% | -$298M-19.7% | -$391M-69.3% | ||
| -156.4%+121pp | -142.9%-33.2pp | -142.1%-39.4pp | -113.7%-12.9pp | -277.3%-180pp | ||
| -$3.19+23.9% | -$3.31-6.8% | -$3.44-9.2% | -$3.17-2.6% | -$4.19-34.7% | ||
| -$3.19+23.9% | -$3.31-6.8% | -$3.44-9.2% | -$3.17-2.6% | -$4.19-34.7% | ||
| 445.8M+20.2% | 418.8M+16.7% | 401.5M+17.2% | 386.4M+18.6% | 371M+20.5% | ||
| 445.4M+20.1% | 418.4M+16.6% | 401.1M+17.0% | 386M+18.4% | 371M+20.5% | ||
| $39M-22.0% | $41M-21.2% | $43M-15.7% | $47M-4.1% | $50M+11.1% | ||
| -$398M+8.7% | -$386M-17.0% | -$375M-17.9% | -$338M-15.4% | -$436M-61.5% | ||
| -$389M+8.7% | -$376M-17.5% | -$365M-18.5% | -$328M-15.5% | -$426M-63.2% | ||
| -$389M+8.7% | -$376M-17.5% | -$365M-18.5% | -$328M-15.5% | -$426M-63.2% | ||
| -164.8%+137pp | -152.2%-28.2pp | -152.1%-35.0pp | -125.2%-10.2pp | -302.1%-192pp | ||
| -$398M+8.7% | -$386M-17.0% | -$375M-17.9% | -$338M-15.4% | -$436M-61.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arcus Biosciences's revenue?
- Arcus Biosciences (RCUS) generated $236.0M in revenue over the trailing twelve months, up 67.4% year over year.
- Is Arcus Biosciences profitable?
- Arcus Biosciences is not currently profitable: it reported a net loss of $369.0M over the trailing twelve months, a -156.4% net margin.
- What is Arcus Biosciences's earnings per share?
- Arcus Biosciences's diluted EPS over the trailing twelve months is $-3.19.
- Where does Arcus Biosciences's income statement data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
